|
Name |
Fusaristatin A
|
Molecular Formula | C36H58N4O7 | |
IUPAC Name* |
3-[6,13-dimethyl-10-methylidene-2,5,9,12-tetraoxo-14-[(5E,7E)-3,7,11-trimethyl-4-oxoheptadeca-5,7-dienyl]-1-oxa-4,8,11-triazacyclotetradec-3-yl]propanamide
|
|
SMILES |
CCCCCCC(C)CC/C=C(\C)/C=C/C(=O)C(C)CCC1C(C(=O)NC(=C)C(=O)NCC(C(=O)NC(C(=O)O1)CCC(=O)N)C)C
|
|
InChI |
InChI=1S/C36H58N4O7/c1-8-9-10-11-13-23(2)14-12-15-24(3)16-19-30(41)25(4)17-20-31-27(6)34(44)39-28(7)35(45)38-22-26(5)33(43)40-29(36(46)47-31)18-21-32(37)42/h15-16,19,23,25-27,29,31H,7-14,17-18,20-22H2,1-6H3,(H2,37,42)(H,38,45)(H,39,44)(H,40,43)/b19-16+,24-15+
|
|
InChIKey |
MNMRSBPSTNMOQK-MAUBWLBLSA-N
|
|
Synonyms |
Fusaristatin A; CHEMBL3086839
|
|
CAS | NA | |
PubChem CID | 76327984 | |
ChEMBL ID | CHEMBL3086839 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 658.9 | ALogp: | 6.3 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 17 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 174.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 47 | QED Weighted: | 0.073 |
Caco-2 Permeability: | -5.019 | MDCK Permeability: | 0.00003970 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.779 |
Human Intestinal Absorption (HIA): | 0.09 | 20% Bioavailability (F20%): | 0.967 |
30% Bioavailability (F30%): | 0.955 |
Blood-Brain-Barrier Penetration (BBB): | 0.541 | Plasma Protein Binding (PPB): | 97.82% |
Volume Distribution (VD): | 0.57 | Fu: | 2.50% |
CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.062 |
CYP2C19-inhibitor: | 0.098 | CYP2C19-substrate: | 0.067 |
CYP2C9-inhibitor: | 0.193 | CYP2C9-substrate: | 0.205 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.277 |
CYP3A4-inhibitor: | 0.93 | CYP3A4-substrate: | 0.245 |
Clearance (CL): | 3.715 | Half-life (T1/2): | 0.606 |
hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.581 |
Drug-inuced Liver Injury (DILI): | 0.053 | AMES Toxicity: | 0.004 |
Rat Oral Acute Toxicity: | 0.898 | Maximum Recommended Daily Dose: | 0.948 |
Skin Sensitization: | 0.439 | Carcinogencity: | 0.219 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.019 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002378 | 0.890 | D0T9TJ | 0.250 | ||||
ENC005276 | 0.357 | D0H2YX | 0.243 | ||||
ENC002373 | 0.339 | D0ZI4H | 0.241 | ||||
ENC005273 | 0.336 | D0K7NQ | 0.237 | ||||
ENC005275 | 0.335 | D0N3NO | 0.233 | ||||
ENC005271 | 0.333 | D09OOV | 0.227 | ||||
ENC005272 | 0.327 | D08FJL | 0.227 | ||||
ENC003950 | 0.326 | D0I4DQ | 0.225 | ||||
ENC002057 | 0.321 | D0M3FJ | 0.222 | ||||
ENC005274 | 0.319 | D0Q8NJ | 0.219 |